GnP

DRUG4 trials

Sponsors

Kochi University, Alterome Therapeutics, Inc., West China Hospital, Immuneering Corporation

Conditions

Advanced Solid TumorsCRC (Colorectal Cancer)CancerNSCLC (Non-small Cell Lung Cancer)PDACPDAC - Pancreatic Ductal AdenocarcinomaPancreatic AdenocarcinomaPancreatic Adenocarcinoma Metastatic

Phase 1

A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations

RecruitingNCT06835569

Alterome Therapeutics, Inc.Advanced Solid Tumors, Cancer, CRC (Colorectal Cancer) +2

Start: 2025-03-05End: 2029-08-01Target: 448Updated: 2026-06-10

Phase 2

Neoadjuvant Chemotherapy for Pancreatic Cancer Followed by GS and GnP

RecruitingNCT05268692

Kochi UniversityPancreatic Adenocarcinoma

Start: 2019-01-01End: 2030-12-31Target: 500Updated: 2022-03-07

Phase 3

A Phase III, Randomized, Clinical Trial of GnP Combined With SBRT and Serplulimab Versus GnP as First-Line Treatment for Patients With Recurrent or Metastatic Pancreatic Cancer (WGOG-PAN 006/ICSBR-2)

Not yet recruitingNCT07336953

West China HospitalPDAC - Pancreatic Ductal Adenocarcinoma

Start: 2026-02-28End: 2028-07-31Target: 198Updated: 2026-01-13

Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

RecruitingNCT07562152

Immuneering CorporationPancreatic Adenocarcinoma, Pancreatic Adenocarcinoma Metastatic, Pancreatic Cancer +5

Start: 2026-06-01End: 2029-02-01Target: 510Updated: 2026-07-17